000 03114nam a22004575i 4500
001 978-1-4614-0598-6
003 DE-He213
005 20140220083239.0
007 cr nn 008mamaa
008 110914s2012 xxu| s |||| 0|eng d
020 _a9781461405986
_9978-1-4614-0598-6
024 7 _a10.1007/978-1-4614-0598-6
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aLeRoith, Derek.
_eeditor.
245 1 0 _aInsulin-like Growth Factors and Cancer
_h[electronic resource] :
_bFrom Basic Biology to Therapeutics /
_cedited by Derek LeRoith.
264 1 _aBoston, MA :
_bSpringer US,
_c2012.
300 _aXII, 284 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development
505 0 _aPreface -- Epidemiology of IGF-1 and Cancer -- Aging and Cancer: The IGF-I Connection -- Obesity, Type 2 Diabetes and Cancer -- IGF System and Breast Cancer -- The Role of Insulin-Like Growth Factor Signaling in Prostate Cancer Development and Progression -- Mouse Models of IGF-1 Deficiency -- Insulin-like Growth Factor Signaling in Pediatric Sarcomas -- Cancer Genes, Tumor Suppressors, and Regulation of IGF-1R Expression in Cancer -- Mouse Models of IGF-1R and Cancer -- Targeting the Insulin-Like Growth Factor-I Receptor in Cancer Therapy -- Targeting Insulin-like Growth Factor (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in Cancer -- Calories and Cancer:  The Role of Insulin-like Growth Factor -- Cancer Cell Metabolism -- Overlaps between the Insulin and IGF-1R and Cancer -- Index.
520 _aThe insulin-like growth factor system has been shown to play a critical role in cancer development and progression. Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics, specifically brings these aspects to the reader. The volume covers the epidemiological aspects of the relationships between circulating insulin and IGF-1 levels and the risk for cancer and cancer-related mortality and in particularly in disease states such as obesity and Type 2 diabetes. It then addresses the basic biology of the system and how the ligands, receptors and IGF-binding proteins affect cancer cell biology and cancer progression. Finally, it discusses the therapeutic potential of inhibiting the receptors using various newly discovered monoclonal antibodies and tyrosine kinase inhibitors that are in preclinical and clinical trials.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aToxicology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aPharmacology/Toxicology.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461405979
830 0 _aCancer Drug Discovery and Development
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-0598-6
912 _aZDB-2-SME
999 _c100884
_d100884